This is a dose block-randomized, double-blind, placebo-controlled, single/multiple dosing, dose-escalation study. The study is designed to describe the relationship between multiple doses and pharmacokinetic/pharmacodynamic parameters of DA-1229 as well as safety profile.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
To characterize the pharmacokinetic/pharmacodynamic of DA-1229 in healthy male subjects
Timeframe: Multiple blood and urine samples will be collected for 120 hours after dosing of DA-1229